Sep 2, 2021
New Partnership with Nikkiso
Nikkiso Medical has graciously provided MediSieve with their PureADJUST hemoperfusion pump as part of an ongoing collaboration.
Nikkiso is one of the world's leading manufacturers of dialysis machines with a mission to keep improving the user-friendliness, safety and efficiency of the complex technology. The main focus of the company is patient safety and responsibility towards their customers. Nikkiso's products and technologies have enabled the creation of entirely new markets in Japan and throughout the world by taking on difficulties that others have deemed unachievable.
PureADJUST is a smart and compact apheresis system. The device offers clear and easy to understand display, and is versatile and easy to use. This enables MediSieve to run experiments in a simplistic and comprehensive manner. MediSieve's CEO George Frodsham has said:
"We are delighted to be working with Nikkiso to ensure that the products we are developing are compatible with their extracorporeal systems. Partnering with companies like Nikkiso is at the centre of our strategy to make sure that we successfully deliver products that are both safe and effective, providing value to patients, doctors and the wider industry."
More about the device:
https://www.nikkiso-europe.eu/en/products/apheresis-equipment/pureadjust-apheresemonitor
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
